Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
131 hedge funds and large institutions have $458M invested in Cymabay Therapeutics in 2018 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 40 increasing their positions, 37 reducing their positions, and 27 closing their positions.
8% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 37
0% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 27
1% less funds holding
Funds holding: 132 → 131 (-1)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
26% less capital invested
Capital invested by funds: $623M → $458M (-$165M)
45% less call options, than puts
Call options by funds: $250K | Put options by funds: $454K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$13.5M |
| 2 |
BlackRock
New York
|
+$6.88M |
| 3 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
+$5.79M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$4.46M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$10.9M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$8.12M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.55M |
| 4 |
AG
Artal Group
Luxembourg
|
-$2.86M |
| 5 |
PA
Perceptive Advisors
New York
|
-$2.67M |
CBAY Hedge Fund Activity: Q4 2018 in Review
131 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q4 2018, worth a combined $458M — down 26% from $623M a quarter earlier.
Fund positioning in CBAY was balanced in Q4 2018: 27 funds opened new positions, 27 closed out, 40 added to existing stakes and 37 trimmed.
The largest buyer was Great Point Partners, opening a new position worth an estimated $13.5M. The largest seller was Fidelity Investments, cutting an estimated $10.9M.
- 131 institutional investors held Cymabay Therapeutics (CBAY) as of Q4 2018, down from 132 in Q3 2018.
- Funds reported $458M of Cymabay Therapeutics stock for Q4 2018, down 26% quarter-over-quarter.
- 27 funds opened new Cymabay Therapeutics positions in Q4 2018 and 27 closed out, a net change of 0 holders.
- The largest Cymabay Therapeutics buyer in Q4 2018 was Great Point Partners, an estimated $13.5M added.
- The largest Cymabay Therapeutics seller in Q4 2018 was Fidelity Investments, an estimated $10.9M sold.
Based on aggregated 13F filings for Q4 2018.